Curated SPACs News
The acquisition strengthens xSeek’s GEO platform by combining AI visibility measurement, strategic recommendations and execution tools.
FOMBONI, Comoros, Sept. 15, 2026 (GLOBE NEWSWIRE) —
The platform confirms its place among the global leaders in social trading
BARCELONA, Spain, Sept. 15, 2026 (GLOBE NEWSWIRE) — The International Trading Institute (ITI) has expanded its education offering beyond its flagship Master’s in Trading, creating a broader set of professional development pathways for traders at different stages of experience.
BARCELONA, Spain, Sept. 15, 2026 (GLOBE NEWSWIRE) — The International Trading Institute (ITI) has expanded its education offering beyond its flagship Master’s in Trading, creating a broader set of professional development pathways for traders at different stages of experience.
Basel, September 15, 2026 – TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company pioneering therapies targeting non-oncogene addiction in cancer, today announced the completion of its Phase I study of monotherapy TT125-802 (NCT06403436) and the presentation of final clinical data from the study at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. The data highlights TT125-802’s confirmed clinical activity as monotherapy in drug-resistant NSCLC and supports CBP/p300 inhibition as a novel therapeutic strategy to address transcriptional drug resistance in solid tumors.
Basel, September 15, 2026 – TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company pioneering therapies targeting non-oncogene addiction in cancer, today announced the completion of its Phase I study of monotherapy TT125-802 (NCT06403436) and the presentation of final clinical data from the study at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. The data highlights TT125-802’s confirmed clinical activity as monotherapy in drug-resistant NSCLC and supports CBP/p300 inhibition as a novel therapeutic strategy to address transcriptional drug resistance in solid tumors.
VIENNA, September 15, 2026 — Aitiologic, a precision medicine company developing tissue-resolved liquid biopsy solutions, today announced the close of a significantly oversubscribed €6.4 million (approximately $7.4 million) seed financing, co-led by Heal Capital and Ananda Impact Ventures. The financing will support ongoing large-scale validation and regulated product development of Aitios®, the company’s multi-modal cell-free DNA (cfDNA) platform, initially for first-trimester preeclampsia risk stratification. Dr. Gordon Sanghera CBE FRS, an established pioneer in molecular diagnostics, participated in the seed round as an investor and will join the company’s advisory board. To further advance the clinical translation of the preeclampsia lead program, Dr. Rebecca Ertl has been appointed Chief Medical Officer.
U.S. Market to Reach USD 418 Million by 2035; Europe to Grow to USD 474.19 Million Amid Rising Pharmaceutical and Specialty Chemical Demand
The platform combines structured English lessons, 164 graded books with narration, songs, grammar, and AI conversation practice to help learners build confidence in English.
Press Release
Telxius boosts global network capacity and efficiency with Nokia 800G Coherent Pluggable deployment
London, UK, Sept. 15, 2026 (GLOBE NEWSWIRE) — Businesses can now accept Visa and Mastercard payments through the same account as their transfers and cards
The initial site assessment will evaluate USREL’s Orangeville, Utah facility as a potential host for future ThermoLoop® deployment
The Supervisory Board of AS Tallink Grupp (hereinafter the Group) resolved to increase the Group’s share capital by EUR 2,451,661 through the issuance of new ordinary shares. The resolution to increase the share capital was adopted in connection with the exercise of options issued under the share option programme approved by the Group’s General Meeting of Shareholders on 13 June 2023, in accordance with the terms and conditions of the share option programme.